Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival

BACKGROUND: Pathologic complete response (pCR) rates in early stage HER2-positive breast cancer improved after pertuzumab was added to neoadjuvant treatment. However, survival benefit is less-well established and seems mostly limited to node-positive patients. We used national cancer registry data t...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Voort, Anna, Liefaard, Marte C., van Ramshorst, Mette S., van Werkhoven, Erik, Sanders, Joyce, Wesseling, Jelle, Scholten, Astrid, Vrancken Peeters, Marie Jeanne T.F.D., de Munck, Linda, Siesling, Sabine, Sonke, Gabe S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356182/
https://www.ncbi.nlm.nih.gov/pubmed/35921798
http://dx.doi.org/10.1016/j.breast.2022.07.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356182/
https://www.ncbi.nlm.nih.gov/pubmed/35921798
http://dx.doi.org/10.1016/j.breast.2022.07.005

Ejemplares similares